Home » Stocks » Palatin Technologies

Palatin Technologies, Inc. (PTN)

Stock Price: $0.387 USD -0.012 (-3.01%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 88.95M
Revenue (ttm) 117,989
Net Income (ttm) -22.43M
Shares Out 229.86M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $0.387
Previous Close $0.399
Change ($) -0.012
Change (%) -3.01%
Day's Open 0.400
Day's Range 0.387 - 0.410
Day's Volume 1,383,221
52-Week Range 0.355 - 0.899

More Stats

Market Cap 88.95M
Enterprise Value 7.37M
Earnings Date (est) Feb 16, 2021
Ex-Dividend Date n/a
Shares Outstanding 229.86M
Float 220.74M
EPS (basic) -0.10
EPS (diluted) -0.10
FCF / Share 0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 46.39%
Payout Ratio n/a
Shares Short 9.16M
Short Ratio 7.49
Short % of Float 4.15%
Beta 1.50
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 2.16
PS Ratio 753.92
PB Ratio 1.14
Revenue 117,989
Operating Income -23.61M
Net Income -22.43M
Free Cash Flow 41.26M
Net Cash 81.59M
Net Cash / Share 0.35
Gross Margin -11,731.10%
Operating Margin -20,007.61%
Profit Margin -19,006.90%
FCF Margin 34,972.36%
ROA -15.55%
ROE -24.82%
ROIC 2,662.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.17*
(460.72% upside)
Low
1.50
Current: $0.387
High
3.00
Target: 2.17
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue0.1260.3067.1344.72-12.95-0.010.071.48
Revenue Growth-99.8%-10.18%50.11%-----85.95%-95%-
Gross Profit0.1260.3067.1344.72-12.95-0.010.071.48
Operating Income-23.6135.7425.93-10.57-49.25-17.29-15.79-15.59-18.79-13.65
Net Income-22.4335.7724.70-13.33-51.71-17.67-13.93-20.86-17.25-12.82
Shares Outstanding23520819818415712110797.6234.9020.08
Earnings Per Share-0.100.160.12-0.07-0.33-0.15-0.13-0.21-0.49-0.64
EPS Growth-33.33%--------
Operating Cash Flow41.33-21.781.7012.88-47.36-13.36-12.21-13.65-15.49-11.03
Capital Expenditures-0.06-0.04-0.02-0.13-0.02--0.01-0.050.480.01
Free Cash Flow41.26-21.821.6812.75-47.38-13.36-12.21-13.70-15.01-11.02
Cash & Equivalents82.8543.5138.0040.459.3827.3012.1824.424.1819.22
Total Debt1.270.336.2814.1219.529.85-0.020.040.08
Net Cash / Debt81.5943.1831.7226.33-10.1417.4512.1824.404.1419.14
Assets85.0510539.0256.8310.8629.4712.5625.075.3821.17
Liabilities4.884.1912.0562.0028.4417.272.772.103.552.98
Book Value80.1710126.96-5.16-17.5912.209.7922.981.8318.19
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Palatin Technologies, Inc.
Country United States
Employees 20
CEO Carl Spana

Stock Information

Ticker Symbol PTN
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: PTN
IPO Date October 28, 1993

Description

Palatin Technologies, a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.